NASDAQ · GAIN
Gladstone Investment Corp.
$15.27+$0.19 (+1.26%)
Gladstone Investment Corp.’s quoted price sits in the upper half of its reported 52-week range, 10.91% below the high.
Loading market information…
NYSE · HQL · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Tekla Life Sciences Investors’s quoted price sits in the lower half of its reported 52-week range, 17.34% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Tekla Life Sciences Investors’s forward annual dividend is $2.48 per share, paid quarterly. The forward yield is 13.23% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tekla Life Sciences Investors’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:23 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$15.27+$0.19 (+1.26%)
Gladstone Investment Corp.’s quoted price sits in the upper half of its reported 52-week range, 10.91% below the high.
$19.13+$0.37 (+1.97%)
Gladstone Capital Corporation’s quoted price sits in the lower half of its reported 52-week range, 11.97% below the high.
$46.39+$0.54 (+1.18%)
Source Capital, Inc.’s quoted price sits in the lower half of its reported 52-week range, 7.97% below the high.
$18.08+$0.17 (+0.95%)
Barings Corporate Investors’s quoted price sits in the lower half of its reported 52-week range, 15.91% below the high.
$4.22+$0.07 (+1.69%)
BlackRock TCP Capital Corp.’s quoted price sits in the lower half of its reported 52-week range, 32.48% below the high.
$2.64+$0.02 (+0.76%)
Eagle Point Credit Company Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.07% below the high.
$7.11+$0.31 (+4.56%)
CION Investment Corporation’s quoted price sits in the lower half of its reported 52-week range, 31.63% below the high.
$9.30+$0.29 (+3.22%)
Crescent Capital BDC, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.74% below the high.
